Leerink Partnrs Issues Optimistic Estimate for ABT Earnings

Key Points

• Leerink Partners has raised their Q4 2025 earnings per share estimate for Abbott Laboratories from $1.47 to $1.48, indicating a positive outlook for the company's financial performance.
• Abbott Laboratories recently announced a quarterly dividend of $0.59 per share, representing an annualized dividend of $2.36 with a yield of 1.8%.
• Multiple analysts have upgraded their price targets for Abbott Laboratories, with the consensus price target now set at $146.17, reflecting strong market confidence in the stock.

Abbott Laboratories (NYSE:ABT - Free Report) - Leerink Partnrs upped their Q4 2025 earnings per share estimates for shares of Abbott Laboratories in a research note issued to investors on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now expects that the healthcare product maker will earn $1.48 per share for the quarter, up from their prior estimate of $1.47. The consensus estimate for Abbott Laboratories' current full-year earnings is $5.14 per share.

Other equities analysts have also recently issued research reports about the company. Evercore ISI boosted their target price on Abbott Laboratories from $140.00 to $144.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 7th. The Goldman Sachs Group upped their target price on Abbott Laboratories from $153.00 to $157.00 and gave the company a "buy" rating in a research note on Wednesday, October 1st. Royal Bank Of Canada increased their price target on Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 15th. Morgan Stanley upped their price objective on Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Finally, Raymond James Financial lowered their price target on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $146.17.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $129.35 on Thursday. The stock has a market cap of $225.13 billion, a P/E ratio of 16.21, a P/E/G ratio of 2.53 and a beta of 0.69. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The stock has a 50 day moving average of $132.59 and a two-hundred day moving average of $131.60. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting analysts' consensus estimates of $1.30. The business had revenue of $11.37 billion during the quarter, compared to analysts' expectations of $11.40 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company's revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories's dividend payout ratio (DPR) is 29.57%.

Insider Activity

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares of the company's stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.46% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ABT. Carr Financial Group Corp boosted its position in Abbott Laboratories by 2.0% in the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker's stock valued at $520,000 after buying an additional 76 shares in the last quarter. Tortoise Investment Management LLC lifted its position in shares of Abbott Laboratories by 10.7% during the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker's stock worth $108,000 after purchasing an additional 77 shares in the last quarter. Mayflower Financial Advisors LLC lifted its position in shares of Abbott Laboratories by 0.5% during the first quarter. Mayflower Financial Advisors LLC now owns 17,327 shares of the healthcare product maker's stock worth $2,298,000 after purchasing an additional 78 shares in the last quarter. Gemmer Asset Management LLC lifted its position in shares of Abbott Laboratories by 2.9% during the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker's stock worth $368,000 after purchasing an additional 78 shares in the last quarter. Finally, FF Advisors LLC lifted its holdings in Abbott Laboratories by 4.3% in the second quarter. FF Advisors LLC now owns 1,904 shares of the healthcare product maker's stock valued at $259,000 after buying an additional 79 shares during the period. Institutional investors own 75.18% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.